Literature DB >> 33415372

Sex-specific associations of serum insulin-like growth factor-1 with bone density and risk of fractures in Chinese patients with type 2 diabetes.

F Lv1, X Cai2, R Zhang1, L Zhou1, X Zhou1, X Han1, L Ji3.   

Abstract

We evaluated the associations of serum insulin-like growth factor-1 (IGF-1) with bone mineral density (BMD) and risk of fractures in Chinese patients with type 2 diabetes (T2D). We found positive associations between IGF-I and BMD and negative associations between IGF-I and all three modified 10-year probabilities of MOFs and HFs in men, but not in women.
INTRODUCTION: The objective was to investigate the associations of serum insulin-like growth factor-1 (IGF-1) with bone mineral density (BMD) and risk of fractures in Chinese patients with type 2 diabetes (T2D) in each gender.
METHODS: This was a cross-sectional, retrospective study that included men over 50 years and postmenopausal women with T2D without medical conditions or medications known to significantly affect BMD or serum IGF-I levels. Data of IGF-1, bone metabolism markers, lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD were obtained; 10-year probability of major osteoporotic fractures (MOFs) and hip fractures (HFs) was calculated and modified with rheumatoid arthritis, femoral neck T-score, and age. Correlations of IGF-1 levels with bone metabolism and risk of fractures were statistically analyzed in men and women, respectively.
RESULTS: A total of 391 patients, including 226 men and 165 women, were included. The age, serum fasting C-peptide, glycosylated hemoglobin (HbA1c), bone formation marker, and all three modified 10-year probabilities of MOFs and HFs were higher in women than those in men (all p < 0.05). The levels of 25 hydroxyvitamin D (25OHD), IGF-1, and BMD were lower in women than those in men (all p < 0.05). In men, IGF-1 was positively correlated with FN and TH BMD (FN BMD: r = 0.267, p < 0.001; TH BMD: r = 0.235, p < 0.001) and negatively correlated with all three modified 10-year probabilities of MOFs (RA-modified MOFs: r = - 0.289, p < 0.001; age-modified MOFs: r = - 0.237, p < 0.001; FN T-score-modified MOFs: r = - 0.280, p < 0.001) and HFs (RA-modified HFs: r = - 0.291, p < 0.001; age-modified HFs: r = - 0.271, p < 0.001; FN T-score-modified HFs: r = - 0.270, p < 0.001), while no significant correlations were found between serum IGF-I and BMD and three modified 10-year probability in women.
CONCLUSIONS: According to this study, we found sex differences in the associations of serum IGF-1 with BMD and risk of fractures in Chinese patients with T2D. These results suggested that increasing serum IGF-1 might be a clinical target for protecting fractures in T2D, especially in men.

Entities:  

Keywords:  Bone mass; Insulin-like growth factor-1; Risk of fractures; Sex difference; Type 2 diabetes

Mesh:

Substances:

Year:  2021        PMID: 33415372     DOI: 10.1007/s00198-020-05790-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes.

Authors:  Ann V Schwartz; Eric Vittinghoff; Douglas C Bauer; Teresa A Hillier; Elsa S Strotmeyer; Kristine E Ensrud; Meghan G Donaldson; Jane A Cauley; Tamara B Harris; Annemarie Koster; Catherine R Womack; Lisa Palermo; Dennis M Black
Journal:  JAMA       Date:  2011-06-01       Impact factor: 56.272

2.  Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  I Kanazawa; T Yamaguchi; T Sugimoto
Journal:  Osteoporos Int       Date:  2010-06-08       Impact factor: 4.507

3.  Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry.

Authors:  William D Leslie; Helena Johansson; Eugene V McCloskey; Nicholas C Harvey; John A Kanis; Didier Hans
Journal:  J Bone Miner Res       Date:  2018-07-16       Impact factor: 6.741

Review 4.  Osteoporosis and the growth hormone-insulin-like growth factor axis.

Authors:  Piet P M M Geusens; Steven Boonen
Journal:  Horm Res       Date:  2002

Review 5.  DXA-Based Measurements in Diabetes: Can They Predict Fracture Risk?

Authors:  G Isanne Schacter; William D Leslie
Journal:  Calcif Tissue Int       Date:  2016-09-03       Impact factor: 4.333

Review 6.  Growth hormone, insulin-like growth factors, and the skeleton.

Authors:  Andrea Giustina; Gherardo Mazziotti; Ernesto Canalis
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

7.  Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus.

Authors:  I Kanazawa; T Yamaguchi; M Yamamoto; M Yamauchi; S Yano; T Sugimoto
Journal:  Osteoporos Int       Date:  2007-07-14       Impact factor: 4.507

8.  Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes.

Authors:  Mohammed-Salleh M Ardawi; Daad H Akhbar; Abdulrahman Alshaikh; Maimoona M Ahmed; Mohammed H Qari; Abdulrahim A Rouzi; Ahmed Y Ali; Adel A Abdulrafee; Mamdouh Y Saeda
Journal:  Bone       Date:  2013-07-09       Impact factor: 4.398

Review 9.  Diagnosis and management of bone fragility in diabetes: an emerging challenge.

Authors:  S L Ferrari; B Abrahamsen; N Napoli; K Akesson; M Chandran; R Eastell; G El-Hajj Fuleihan; R Josse; D L Kendler; M Kraenzlin; A Suzuki; D D Pierroz; A V Schwartz; W D Leslie
Journal:  Osteoporos Int       Date:  2018-07-31       Impact factor: 4.507

10.  Osteoporosis and Fragility Fractures in Type 2 Diabetes.

Authors:  Iacopo Chiodini; Antonino Catalano; Luigi Gennari; Agostino Gaudio
Journal:  J Diabetes Res       Date:  2020-07-14       Impact factor: 4.011

View more
  1 in total

1.  Serum Insulin-Like Growth Factor 1 Levels, Facture Risk Assessment Tool Scores and Bone Disorders in Patients with Primary Biliary Cholangitis.

Authors:  Chisato Saeki; Tsunekazu Oikawa; Kaoru Ueda; Masanori Nakano; Yuichi Torisu; Masayuki Saruta; Akihito Tsubota
Journal:  Diagnostics (Basel)       Date:  2022-08-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.